Showing 1 - 7 results of 7 for search 'Xue-Zhi Hao', query time: 0.03s Refine Results
  1. 1
    A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations

    A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations by Hong‐Shuai Li, Jin‐Yao Zhang, Xiang Yan, Hai‐Yan Xu, Xue‐Zhi Hao, Pu‐Yuan Xing, Yan Wang

    Published 2022-02-01
    Get full text
    Article
  2. 2
    Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases

    Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases by Jinyao Zhang, Yan Wang, Ziling Liu, Lin Wang, Yu Yao, Yutao Liu, Xue Zhi Hao, Jianyang Wang, Puyuan Xing, Junling Li

    Published 2021-12-01
    Get full text
    Article
  3. 3
    Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review

    Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review by Hong-Shuai Li, Si-Yu Lei, Jun-Ling Li, Pu-Yuan Xing, Xue-Zhi Hao, Fei Xu, Hai-Yan Xu, Yan Wang

    Published 2022-08-01
    Get full text
    Article
  4. 4
    Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer

    Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer by Si‐Yu Lei, Hai‐Yan Xu, Hong‐Shuai Li, Ya‐Ning Yang, Fei Xu, Jun‐Ling Li, Zhi‐Jie Wang, Pu‐Yuan Xing, Xue‐Zhi Hao, Yan Wang

    Published 2023-08-01
    Get full text
    Article
  5. 5
    The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.

    The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. by Ning-Ning Zhang, Yu-Tao Liu, Li Ma, Lin Wang, Xue-Zhi Hao, Zheng Yuan, Dong-Mei Lin, Dan Li, Yu-Jie Zhou, Hua Lin, Xiao-Hong Han, Yan Sun, Yuankai Shi

    Published 2014-01-01
    Get full text
    Article
  6. 6
    Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon <i>EGFR</i> Mutations: A Comparative Cohort Study in China (AFANDA Study)

    Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon <i>EGFR</i> Mutations: A Co... by Hong-Shuai Li, Shou-Zheng Wang, Hai-Yan Xu, Xiang Yan, Jin-Yao Zhang, Si-Yu Lei, Teng Li, Xue-Zhi Hao, Tao Zhang, Guang-Jian Yang, Li-Qiang Zhou, Peng Liu, Yu-Ying Wang, Xing-Sheng Hu, Pu-Yuan Xing, Yan Wang

    Published 2022-10-01
    Get full text
    Article
  7. 7
    Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients

    Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients by Li‐Ling Huang, Xing‐Sheng Hu, Yan Wang, Jun‐Ling Li, Hong‐Yu Wang, Peng Liu, Jian‐Ping Xu, Xiao‐Hui He, Xue‐Zhi Hao, Pei‐Di Jiang, Yu‐Tao Liu, Jian Luo, Sheng‐Yu Zhou, Jin‐Wan Wang, Jian‐Liang Yang, Yan Qin, Peng Yuan, Lin Lin, Yuan‐Kai Shi

    Published 2021-07-01
    Get full text
    Article

Search Tools: